Article 138(3) of the EPC: how Turkish courts treat amended patent claims

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Article 138(3) of the EPC: how Turkish courts treat amended patent claims

Sponsored by

gun+partners_40th-logo.jpg
Statue of Justice in Çeşmealtı, Turkey

A Turkish case highlights the importance of Article 138(3) when patent claims are amended during an invalidation action, say Selin Sinem Erciyas, Aysel Korkmaz Yatkın, and Bengü Şen Gürakan of Gün + Partners

Pursuant to Article 138(3) of the European Patent Convention (EPC), a patent proprietor is entitled to limit the patent by amending the claims in proceedings before the competent court or authority relating to the validity of the European patent. According to the same provision, the patent, as limited, shall form the basis of the proceedings.

At the same time, under the Turkish Industrial Property Code (Law No. 6769), patent validity is, in principle, assessed based on the claims as granted. The interaction between these two frameworks creates a practical question: whether and to what extent Turkish courts may consider amended claims submitted before the Turkish Patent and Trademark Office (TURKPATENT) for a European patent validated in Turkey (officially Türkiye), after the initiation of invalidation proceedings before the Turkish courts.

A recent dispute offers a clear practical answer.

Background to the case

In an invalidation action brought by a generic company, initial expert reports indicated that the patent faced a serious risk of revocation in its granted form. As the case progressed, the patent proprietor limited the claims in parallel with proceedings before the EPO, had these amendments filed before TURKPATENT, and submitted them to the court.

Following the acceptance of the claim limitation request by TURKPATENT, the Intellectual and Industrial Property Court (the IP Court) ordered an expert report to assess whether any grounds for invalidation existed, taking into account the amended set of claims. Although the experts had previously opined in their report that the patent should be invalidated based on the original set of claims, they subsequently concluded that the limited set of claims did not contain grounds for invalidation.

In this context, the IP Court was requested to render its decision accordingly, it being emphasised that Article 138(3) of the EPC clearly grants the patent proprietor the right to amend the claims of a European patent, and that, in such circumstances, the national court must assess the invalidation allegations of the disputed patent on the basis of the final amended version of the claims.

The plaintiff objected to the consideration of these amendments, arguing that the invalidation assessment should be carried out with the claims as they existed at the time of filing of the invalidation action. According to the plaintiff’s argument, allowing amendments at a later stage would undermine procedural certainty and adversely affect the position of the plaintiff.

The ruling and its implications

Despite the plaintiff’s objections, the IP Court and the Regional Court of Appeal assessed the patent based on the amended claim set and ultimately dismissed the invalidation action. This approach indicates that Turkish courts would – as they should – consider claim amendments submitted as per Article 138(3) of the EPC during the proceedings when assessing an invalidation action.

This practice highlights a crucial point: the right to limit a patent by amending its claims under Article 138(3) of the EPC is far from merely theoretical—it produces concrete and meaningful procedural consequences in Turkish litigation. In the authors’ view, considering the functional relationship between the right to limitation under the EPC and the national invalidation procedure, claim amendments submitted under Article 138(3) of the EPC should be regarded as an important part of the patent proprietor’s defence. Accordingly, Turkish courts should continue to assess patent validity based on the amended claims.

Indeed, the interaction between Article 138(3) of the EPC and the Turkish invalidation framework demonstrates that claim amendments are not a merely procedural formality but a substantive mechanism capable of directly influencing the outcome of patent disputes in Türkiye. The examined case makes clear that Turkish courts are willing to take into account post-grant claim limitations accepted by TURKPATENT and to reassess patent validity on the basis of the amended claims, even where earlier expert opinions pointed towards invalidation.

This approach reflects a pragmatic and harmonised interpretation of the EPC within the Turkish legal system. By recognising amended claims as the operative basis of the dispute, courts ensure that the patent is evaluated in its legally valid and current form, rather than being confined to an outdated version that no longer reflects the scope of protection sought by the proprietor.

From a strategic standpoint, this practice reinforces the importance of Article 138(3) of the EPC as a key defensive tool in invalidation proceedings. Patent proprietors should therefore carefully consider timely claim limitation—whether before the EPO or TURKPATENT—as part of their litigation strategy.

more from across site and SHARED ros bottom lb

More from across our site

The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Matteo Di Lernia, advocate at LCA Studio Legale, unpicks the CJEU’s ruling in M.M. Ristorazione v Villa Ramazzini, including its impact on litigation strategies
Leaders at IP boutique say the decision to pursue sponsorless partnership with the specialised investment arm of a private equity firm comes at a time of ‘profound transformation’ in the profession
Gift this article